Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Smart Drugs and Orthomolecular Substances for Aging Minds

Smart Drugs and Orthomolecular Substances for Aging Minds The aging of the nervous system is not fully understood, but defects in mitochondrial energy production, originating in mitochondrial DNA mutations, have been implicated, along with neurotransmitter deficiencies and excitotoxic mechanisms. Molecules involved in energy metabolism, such as NADH, acetyl-L-carnitine, ubiquinone, and lipoic acid, are potentially therapeutic. Various natural and synthetic Pharmaceuticals can retard senility by influencing neurotransmitters, modulating NMDA-receptor mechanisms, enhancing circulation and metabolism, acting as antioxidants, and in other ways. Certain Pharmaceuticals, including meclofenoxate, ergoloid mesylates, piracetam, ginkgo, and vinpocetine, have plural effects in the nervous system. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Advancement in Medicine Springer Journals

Smart Drugs and Orthomolecular Substances for Aging Minds

Huemer, Richard
Journal of Advancement in Medicine , Volume 12 (2) – Sep 30, 2004
Download PDF
13 pages

Loading next page...
 
/lp/springer-journals/smart-drugs-and-orthomolecular-substances-for-aging-minds-2206uuQSOO
Publisher
Springer Journals
Copyright
Copyright © 1999 by Human Sciences Press, Inc.
Subject
Medicine & Public Health; Public Health
ISSN
0894-5888
eISSN
1573-9767
DOI
10.1023/B:JAME.0000008703.34341.9e
Publisher site
See Article on Publisher Site

Abstract

The aging of the nervous system is not fully understood, but defects in mitochondrial energy production, originating in mitochondrial DNA mutations, have been implicated, along with neurotransmitter deficiencies and excitotoxic mechanisms. Molecules involved in energy metabolism, such as NADH, acetyl-L-carnitine, ubiquinone, and lipoic acid, are potentially therapeutic. Various natural and synthetic Pharmaceuticals can retard senility by influencing neurotransmitters, modulating NMDA-receptor mechanisms, enhancing circulation and metabolism, acting as antioxidants, and in other ways. Certain Pharmaceuticals, including meclofenoxate, ergoloid mesylates, piracetam, ginkgo, and vinpocetine, have plural effects in the nervous system.

Journal

Journal of Advancement in Medicine – Springer Journals

Published: Sep 30, 2004

References

  • The Roots of Molecular Medicine
    Harman, D.
  • Involvement of free radicals in ageing: a consequence or cause of senescence
    Nohl, H.
  • Genetic instability as the primary cause of human aging
    Strehler, BL.
  • Loss of hybridizable ribosomal DNA from human post-mitotic tissues during aging: I. Age-dependent loss in human myocardium
    Strehler, BL; Chang, MP; Johnson, LK.
  • Mitochondrial studies in senescent mice-II. Specific activity, buoyant density, and turnover of mitochondrial DNA
    Huemer, RP; Lee, KD; Reeves, AE
  • An update on the oxygen stress-mitochondrial mutation theory of aging: genetic and evolutionary implications
    Miquel, J.
  • Mitochondrial DNA mutations in human diseases: a review
    Lestienne, P.
  • Nuclear but not mitochondrial genome involvement in human age-related mitochondrial dysfunction. Functional integrity of mitochondrial DNA from aged subjects
    Hayashi, J; Ohta, S; Kagawa, Y
  • Mitochondrial DNA in aging and disease
    Wallace, DC.
  • Origin and functional consequences of the complex I defect in Parkinson's disease
    Swerdlow, RH; Parks, JK; Miller, SW
  • The content of intracellular mitochondrial DNA is decreased by l-methyl-4-phenylpyridinium ion (MPP+)
    Miyako, K; Kai, Y; Irie, T
  • Parenteral application of NADH in Parkinson's disease: clinical improvement partially due to stimulation of endogenous levodopa biosynthesis
    Kuhn, W; Muller, T; Winkel, R
  • Detection of point mutations in codon 331 of mitochondrial NADH dehydrogenase subunit 2 in Alzheimer's brains
    Lin, FH; Wisniewski, HM; Hwang, YW
  • Regional heterogeneity of mtDNA heteroplasmy in Parkinsonian brain
    Schnopp, NM; Kosel, S; Egensperger, R
  • No association of mutations at nucleotide 5460 of mitochondrial NADH dehydrogenase with Alzheimer's disease
    Kosel, S; Egensperger, R; Mehracin, P
  • Coenzyme nicotinamide adenine dinucleotide: new therapeutic approach for improving dementia of the Alzheimer type
    Birkmayer, JG
  • Absorption, tolerability and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients
    Shults, CW; Beal, MF; Fontaine, D
  • Neuroprotection by the metabolic antioxidant alpha-lipoic acid
    Packer, L; Tritschler, HJ; Wessel, K.
  • Neuroprotective effects of alpha-lipoic acid and its enantiomers demonstrated in rodent models of cerebral ischemia
    Wolz, P; Krieglstein, J.
  • A controlled trial of selegiline, alpha tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study
    Sano, M; Ernesto, C; Thomas, RG.
  • A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease
    Thal, LJ; Carta, A; Clarke, WR
  • Mitochondrial DNA transcription and translation in aged rat
    Gadaleta, MN; Petruzzella, V; Daddabbo, L
  • The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases
    Schulz, JB; Matthews, RT; Klockgether, T
  • [b]-Amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage
    Koh, J; Yang, LL; Cotman, CW.
  • On the possible role of nootropica in geriatric prevention and therapy
    Zs Nagy, I.
  • Smart Drugs II. The next generation
    Dean, W; Morgenthaler, J; Fowkes, SW.
  • Cognitive enhancement: new strategies for stimulating cholinergic, glutamatergic, and nitric oxide systems
    Ingram, DK; Shimada, A; Spangler, EL
  • Pharmacological restoration of scopolamine-impaired memory
    Petkov, VV; Vuglenova, Y.
  • Effect of the combination of the benzodiazepine tranquilizer medazepam and the nootropic agent meclofenoxate on the activity of rat brain muscarinic receptors
    Popova, JS; Petkov, VD.
  • New Drugs for Alzheimer's disease
    Pelagarza, V. W.
  • Current pharmacotherapies for Alzheimer's disease
    Knopman, DS.
  • New cholinergic therapies: treatment tools for the psychiatrist
    Tune, LE; Sunderland, T.
  • Double-blind trial of Huperzine-A (HUP) on cognitive deterioration in 314 cases of benign senescent forgetfulness, vascular dementia, and Alzheimer's disease
    Ma, YX; Zhu, Y; Gu, YD
  • Age-associated memory impairment: assessing the role of nitric oxide
    Meyer, RC; Spangler, EL; Kametani, H.
  • Botanical Influences on Illness
    Werbach, MR; Murray, MT.
  • A placebo-controlled, double-blind randomized trial of an extract of Ginkgo biloba for dementia
    LeBars, PL; Katz, MM; Berman, N
  • Morphological alterations of synaptic mitochondria during aging: the effect of Hydergine treatment
    Bertoni-Freddari, C; Fattoretti, P; Casoli, T
  • Upregulation of antioxidant enzyme activities by Deprenyl
    Kitani, K; Miyasaka, K; Kanai, S
  • Suppression of hydroxyl radical formation and protection of nigral neurons by 1-Deprenyl (selegiline)
    Wu, RM; Murphy, DL; Chiueh, CC.
  • Pharmacological intervention in age-associated brain disorders by Flupirtine: Alzheimer's and prion diseases
    Perovic, S; Böhm, M; Meesters, E
  • Apolipoprotein E and Alzheimer's disease
    Roses, AD.